Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery.

Our ultimate goal is to optimally allocate approved treatments to cancer patients who will benefit from them, while creating novel therapies that are purpose-designed for patients who don't respond to available treatments.

The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples with matched blood into 3D immune-microtumors to test potential treatment options and combinations ex vivo. A proprietary computer vision/DL pipeline finds image-based spatial biomarkers in time-course 3D microscopy data of patient 3D immune-microtumors. Each treatment option is compared using these image biomarkers to predict which treatments have high potential efficacy for each patient. 

Patient data and excess tissue/blood feed into a multi-omics pipeline, which allows us to find novel druggable targets in patients who don't respond to approved therapies. These targets are then developed into our in-house drug discovery pipeline, which eventually feeds back into clinical care through our predictive biomarker platform.


SOSV

RebelBio

Greater London Authority

Hoxton Ventures

Fly Ventures

Wavemaker 360

Octopus Ventures

Compound

Crista Galli Ventures

Pear Bio

Our Winter 2023 newsletter now out, with a focus on our clinical trial work

https://lnkd.in/ewiz_XVw

Let us know if you have questions, or want to know more about our clinical trials!

The Pear Bio team is excited to have set up our first US lab in the Boston area at ABI-LAB 2 this month! The facilities and support provided by the team are second to none 🇺🇸  🇺🇸  🇺🇸 

This lab will focus on US clinical trials & lab developed testing.

We are looking forward to this new chapter for the company!

Really delighted that we have support from a range of charities for our trials.

Pear-Tree2 in kidney cancer from Kidney Cancer UK
Pear-TNBC in Triple Negative Breast Cancer from Breast Cancer Now

and both are open across a range of hospitals

https://lnkd.in/d5iYhvgV
https://lnkd.in/dYrU_EiZ

To read more about our trials, see here: https://lnkd.in/dvJkA5CN

Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Feb 6, 2024 10:23 AM	dc9c7cde
translate crunchbase fundingrounds	general
peers	general	Feb 6, 2024 10:23 AM	963c6158
news basic	general
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:PEARBIO

Pear Bio